Stockreport

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's P [Read more]